Go Deep
Caribou Biosciences, Inc.
Caribou Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,132 | -0.4 | 0.51 | 0.27 | 44.76 |
| Oct 2026 | 23,151 | -0.4 | 0.50 | 0.27 | 43.69 |
| Oct 2026 | 23,142 | -0.4 | 0.51 | 0.27 | 44.13 |
| Oct 2026 | 23,132 | -0.4 | 0.51 | 0.27 | 44.51 |
| Oct 2026 | 23,143 | -0.4 | 0.51 | 0.27 | 43.99 |
| Oct 2026 | 23,036 | -0.5 | 0.57 | 0.27 | 49.21 |
| Oct 2026 | 22,986 | -0.5 | 0.59 | 0.27 | 51.49 |
| Oct 2026 | 22,955 | -0.5 | 0.61 | 0.27 | 52.86 |
Caribou Biosciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,499,000.0 | 2,397,000.0 | 3,941,000.0 | 2,198,000.0 |
| Net Profit | -24,282,000.0 | -25,085,000.0 | -26,488,000.0 | -27,548,000.0 |
| EPS | -0.2 | -0.3 | -0.3 | -0.3 |
Caribou Biosciences, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 11,159,000.0 | 9,994,000.0 | 34,477,000.0 | 13,851,000.0 | — |
| Net Profit | -148,125,000.0 | -149,105,000.0 | -102,070,000.0 | -99,421,000.0 | — |
| EPS | -1.6 | -1.6 | -1.4 | -1.6 | — |
Caribou Biosciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 175,367,000.0 | 313,313,000.0 | 432,209,000.0 | 373,765,000.0 | — |
| Total Liabilities | 53,192,000.0 | 60,362,000.0 | 63,808,000.0 | 72,894,000.0 | — |
| Total Equity | 122,175,000.0 | 252,951,000.0 | 368,401,000.0 | 300,871,000.0 | — |
Owes vs Owns
Caribou Biosciences, Inc. owed $0.31 for every $1 it owned in Jun 2026, up from $0.20 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.31× | 0.30× | 0.19× | 0.15× | 0.20× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Caribou Biosciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 79.5%Receivables 1.7%Fixed assets (tangible) 13.9%Long-term investments 2.0%Other assets 2.9%
How it's funded — Dec 2025
Short-term debt 0.7%Long-term debt 14.8%Payables 3.3%Other liabilities 11.5%Shareholders' equity 69.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 139.3 | 209.5 | 328.8 | 247.7 |
| Receivables | 3.0 | 3.3 | 3.9 | 4.7 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 24.4 | 39.3 | 40.5 | 34.9 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 3.5 | 49.1 | 51.3 | 77.1 |
| Other assets | 5.1 | 12.1 | 7.7 | 9.5 |
| Liabilities & equity | ||||
| Short-term debt | 1.2 | 1.4 | 1.2 | 1.0 |
| Long-term debt | 26.0 | 25.1 | 25.9 | 26.8 |
| Payables | 5.8 | 2.5 | 3.1 | 1.1 |
| Other liabilities | 20.2 | 31.4 | 33.6 | 44.0 |
| Shareholders' equity | 122.2 | 253.0 | 368.4 | 300.9 |
| Net tangible assets | 122.2 | 253.0 | 368.4 | 300.9 |
Caribou Biosciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -110,992,000.0 | -138,200,000.0 | -93,291,000.0 | -90,966,000.0 | — |
| Investing Activities | 102,238,000.0 | 86,607,000.0 | -68,183,000.0 | -93,249,000.0 | — |
| Financing Activities | 4,821,000.0 | 16,724,000.0 | 154,298,000.0 | 2,133,000.0 | — |